Navigation Links
Biologic Treatment of Rheumatoid Arthritis Is Low in Brazil, According to Kantar Health Research

New York, NY (PRWEB) September 14, 2013

Despite the impairment caused by their disease, only 13 percent of rheumatoid arthritis patients in Brazil who are eligible for biologic therapy according to clinical guidelines are actually using a biologic, according to new findings from Kantar Health’s National Health and Wellness Survey (NHWS). The research will be presented today at the ISPOR (International Society for Pharmacoeconomics and Outcomes Research) 4th Latin America Conference in Buenos Aires.

Recently updated treatment recommendations from the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) suggest that rheumatoid arthritis patients who fail to respond to a disease-modifying antirheumatic drug (DMARD) be administered a biologic DMARD. According to NHWS, more than half of moderate-to-severe rheumatoid arthritis patients in Brazil are eligible for biologic DMARD therapy according to these guidelines; however, only 13 percent actually use these therapies.

Biologic DMARDs are injectable treatments that are typically much more expensive than traditional DMARDs. Only 20 percent of rheumatoid arthritis patients in Brazil reported a monthly income of more than R$10,000, suggesting that they would have significantly worse access to an expensive treatment. In addition, nearly 30 percent of these patients said they have a fear of needles, which might also affect use of an injectable therapy.

“The majority of patients with rheumatoid arthritis in Brazil have high levels of disease severity, and these patients report more physical impairment,” said Dave Pomerantz, Senior Vice President, Kantar Health. “However, treatment rates among patients with rheumatoid arthritis were generally modest overall, particularly with respect to the biologic DMARDs. Our research suggests that poor access to these medications and patients’ attitudes may be hindering uptake of biologics, which would delay the progress of the disease.”

Visit Kantar Health’s website to download the full poster, “Unmet Needs and Biologic Use among Patients with Rheumatoid Arthritis in Brazil.”

About the National Health and Wellness Survey (NHWS)
The study’s results were drawn from the 2011 and 2012 Brazil NHWS, a nationally representative, self-administered survey conducted annually. Topics covered include the health status, attitudes, behaviors and outcomes among adults 18 or older.

Kantar Health conducts the NHWS in the U.S., Europe, Asia and Latin America. The survey is the largest self-reported dataset in the healthcare industry.

About Kantar Health
Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech, and medical device and diagnostic companies. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.

Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 700+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. For more information, please visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Kalen Biomedical, LLC Signs Distribution Agreement with Beijing LeBo Biological
2. Molecular Imaging, Inc. Announces New Webinar: Advancing Discovery and Development of Biologics Through Non-Invasive Biodistribution Imaging
3. BCC Research Publishes a New Report On Global Markets for Surveillance and Monitoring of Explosive, Chemical, Biological, and Nuclear (Ecbn) Hazards.
4. Distinct brain disorders biologically linked
5. Biological and Biochemical Product Manufacturing in China Industry Research Report – Now Available from IBISWorld
6. BiologicsMD, Inc. Announces The Appointment of J. David Owens as Chief Executive Officer
7. Statement from the Sensory Processing Disorder Foundation Endorsing New Breakthrough Study Revealing Biological Basis for Sensory Processing Disorders in Kids
8. Advancement in Biologic Protein Expression Webinar Hosted by Selexis SA
9. Silk and cellulose biologically effective for use in stem cell cartilage repair
10. Frequently used biologic agents might cause acute liver injury
11. Men Biologically Programmed to Steer Clear of Friends Wives
Post Your Comments:
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... the conversation at the recent 2015 American Dental Association meeting in Washington D.C. revolved ... can help protect a patient’s overall health. The talk stressed the link between periodontal ...
(Date:11/27/2015)... ... 2015 , ... An inventor, from Hopkinsville, Ky., thought there ... home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. provides ... so, it could help to prevent potential overdose situations. As a result, it ...
(Date:11/27/2015)... LOS ANGELES, CA (PRWEB) , ... November 27, 2015 , ... MPWH, the No.1 Herpes-only ... age of 30 (see Table 1-1 ). More than 3.7 billion people under ... simplex virus type 1 (HSV-1), according to WHO's first global estimates of HSV-1 infection ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... innovative online platform for mental health and wellness consultation, has collaborated with a ... will bridge the knowledge gap experienced by parents and bring advice from parenting ...
(Date:11/27/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk ... Term Support) into its Q-Suite 5.10 product line. , Making the change to ... of Asterisk that will receive not only security fixes, but feature and bug ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... , Nov. 27, 2015  Lannett Company, ... it has completed the acquisition of Kremers Urban ... subsidiary of global biopharmaceuticals company UCB S.A. (Euronext: ... Lannett has acquired KU from UCB for ... certain adjustments, including a customary working capital adjustment, ...
(Date:11/27/2015)... 2015 ... "2016 Global Tumor Marker Testing Market: ... Sales Segment Forecasts, Innovative Technologies, Instrumentation Review, ... their offering. --> ) ... "2016 Global Tumor Marker Testing Market: Supplier ...
(Date:11/26/2015)... UTRECHT , Países Bajos, November 26, 2015 /PRNewswire/ ... con la terapia fotodinámica de Bremachlorin para el cáncer ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Un nuevo enfoque combina la inmunoterapia con la ...   Clinical Cancer Research . --> ...
Breaking Medicine Technology: